Why the study?
Although non-VKA oral anticoagulants have shifted thromboembolism prevention globally, oral anticoagulant prescription trends in China remained unclear.
NOAC use in China increased rapidly between 2012 and 2017, accounting for a disproportionate share of OAC costs relative to patient coverage.
No takes yet. Share an insight, caveat, or question.
Disproportionate NOAC costs in China signal need for affordability monitoring; leaves open optimal OAC strategies in resource-limited settings.
Yu et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: